Allogene (ALLO) Reiterated at Market Outperform by Citizens on Progress in Autoimmune Diseases
Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $6.00 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)